News | June 12, 2009

ICANL Offers New Accreditation Pathway for Lab Innnovation

June 12, 2009 – The Intersocietal Commission for the Accreditation of Nuclear Medicine Laboratories (ICANL) announced that it will accept accreditation applications from laboratories utilizing new technologies and other novel imaging approaches, such as new software algorithms and new camera technologies, that to date are not included within the guidelines published by the professional societies.

Such laboratories will apply for accreditation via the ICANL Online Accreditation application and undergo further evaluation by way of the new Emerging Technologies Pathway.

With emphasis on ensuring quality patient care, the following provisions have been established. When there is a new technology that utilizes parameters that are outside of the currently accepted ICANL Standards, utilization of the new technology must demonstrate the following:

- Clinical validation - The technology must perform, as intended, to produce clinical results that are equal to or better than currently accepted technologies, based on published, peer-reviewed data. This would include a clear delineation of the clinical scenario to which it applies (indications/diagnoses) and the method of utilization (procedure).

- Reproducibility - For instrumentation, there must be clearly defined quality control procedures and data to show stability of the device, when used as indicated.

New Software Algorithms or New Equipment Hardware Technology
Laboratories using standard imaging equipment but utilizing imaging reconstruction algorithms not currently incorporated in the published imaging guidelines (i.e. half-time) or laboratories using new hardware technology with FDA 510K clearance that is not incorporated into professional organization guidelines, are required to perform a physiologic
phantom study to determine defect/image reproducibility using the laboratory's actual imaging parameters. These laboratories are also required to demonstrate compliance with manufacturers' recommended quality control by submitting results of quality control testing. In addition, documentation of adequate training and competency of the technical staff, relevant to the new technology is required.

Pharmaceuticals and Radiopharmaceuticals
Laboratories using FDA approved pharmaceuticals and radiopharmaceuticals, according to FDA labeled uses, are not required to submit additional documentation for accreditation.

Standard Conventional Technology
For laboratories using standard conventional technology and imaging approaches currently incorporated in the guidelines published by the professional societies, no further documentation is required as part of the accreditation process. For instance, laboratories utilizing SPECT imaging based on Anger camera equipment using filtered back projection reconstruction are required to adhere to published guidelines and thus no additional documentation is necessary.

Quality Assessment Patient Simulator Program
Offered jointly by the ICANL and the Society of Nuclear Medicine (SNM), the newly launched Quality Assessment Patient Simulator Program provides laboratories with the physiologic phantom required to identify and quantify areas of abnormality and determine the diagnostic significance of these findings. Laboratories applying through the Emerging Technologies Pathway are required to submit the results of the patient simulator
program to the ICANL for evaluation and grading, based upon objectives judging defect reproducibility and image quality. Laboratory reporting of images will also be evaluated.

The first module to be released, the Cardiac SPECT Phantom, is available to test the applicant laboratory's ability to acquire and process SPECT rest/stress myocardial perfusion studies, identify and quantify areas of perfusion abnormality and determine the diagnostic significance of these findings. Participating laboratories will purchase the Quality Assessment Patient Simulator Program from the ICANL for $500 and will have thirty (30) days from receipt of the patient simulator to submit the results. Laboratories will be required to submit the phantom results/questionnaire and all images used to make the clinical diagnosis, in addition to their laboratory's imaging protocol. The laboratory's submitted results will be graded by the ICANL using objective criteria.

As part of the Quality Assessment Patient Simulator Program, phantoms for general nuclear medicine and PET technology are under development.

"The ICANL seeks a balance between maintaining standards for quality patient care while not impeding the evolution of technology. By offering the new Emerging Technologies Pathway and making available the corresponding ICANL/SNM Quality Assessment Patient Simulator Program, we are providing laboratories with the means and tools by which to evaluate these new technological developments and ensure that they are providing
quality patient care", remarked Sue Abreu, MD, FACNP, President of the ICANL Board of Directors.

To learn more about the ICANL's new Emerging Technologies Pathway and the Quality Assessment Patient Simulator Program during the SNM's 2009 Annual Meeting in Toronto, plan to attend the SNM Arena exhibit hall presentation with Mary Beth Farrell, MS, CNMT, NCT, RT(N), ICANL Technical Manager, and Sue Abreu, MD, FACNP, ICANL President, (Sunday, June 14th at 12pm) or visit the ICANL in booth 115 in the exhibit hall.

Related Content

News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...